Resilience, inflation and earnings growth
“We have raised prices by 8% across our products in the first five months of the year. We expect to take another price hike in the coming months.” We had entered the meeting with Blue Star, a leading air-conditioner company in our portfolio worried about the risks to its growth and profitability, as the second wave of Covid-19 affected consumer demand and raw material costs rose sharply. But the company’s CEO told us about the acceptance of increased prices by their channel partners and customers and strong demand before localised lockdowns were introduced in April. The company had reported a 24% growth in sales and more than doubling of its operating profit in the quarter ended March 2021, compared to the same period last year. He was optimistic about an improvement in their profitability despite a significant increase in raw material costs and was continuing their investments in expanding capacity.
We have closely followed earnings across our portfolio companies to assess how successfully they have emerged from the initial impact of the pandemic. We have been positively surprised. In the quarter ended December 2020, median revenues across our portfolio holdings grew by 14% and median profits by 18% over the same period last year. Growth accelerated in the most recent quarter, as median revenues across the portfolio’s holdings grew by 26% and profits by 39% over the same period last year (albeit this was on a lower base affected by the initial impact of Covid-19). Cash flows have been strong and the balance sheets of almost all our portfolio companies remain in net cash positions1.
We noted some key trends across our investment universe during this period.
- Accelerated market share gains by organised sector companies: Smaller companies in the unorganised sector with limited capital availability and weak information technology (IT) systems struggled to cope with the extended national lockdown last year. This allowed industry leaders to gain significant market share across sectors. Metropolis Healthcare, a leader in the highly fragmented diagnostics industry witnessed 41% growth in its revenues and an almost tripling of its profit in the most recent quarter. Consumers are shifting rapidly from small local laboratories to those of established brands like Metropolis with higher quality standards and accreditations.
- Price hikes to pass on the impact of rising inflation in raw material and labour costs: In industries ranging from electrical products to IT services, customers have accepted significant price increases. KEI Industries, a manufacturer of electrical wires and cables, raised prices of its wires used in household applications by 35% over the last six months. The CEO of Mphasis, a fast-growing IT services company, told us that unlike previous years in which they witnessed consistent pricing pressure from their large corporate clients, most customers have been willing to discuss price hikes due to wage inflation.
- Investments in capacity expansion: There hasn’t been much corporate capital expenditure (capex) during the last decade in India. Recently, sharply rising commodity prices has led to large capex announcements by several commodity producers. Thermax, the largest manufacturer of boilers used across heavy industries indicated a significant improvement in customer enquiries across sectors such as oil & gas, steel and cement after years of weak industrial demand.
Their performance in recent quarters shows that companies across our investment universe have emerged from the pandemic stronger than they were before. Corporate India’s resilience was severely tested over the previous decade, as it dealt with a long-drawn downturn. The material price hikes taken by companies indicates a return of confidence which we have not seen for a long time. In our view, it signals strong underlying demand as well as significant gains in market share by these resilient businesses. One of the key reasons for weak corporate earnings growth in nominal terms in recent years was low inflation. It seems like this is changing and our companies are exercising their pricing power. It is difficult to predict their performance over the next few quarters, as most businesses have been affected by the explosive second wave of Covid-19. Rural demand which had remained strong last year is also likely to be weak in the coming months. Despite this, our conviction in the businesses that we own has become stronger during this period. Their recent performance gives us confidence that as our companies emerge from the pandemic, they will deliver exceptionally strong earnings growth in the years ahead.
1 Source: Bloomberg, FSSA Investment Managers, as at 31 May 2021
People before profit
As the deadly second wave of Covid-19 has ravaged India, we have witnessed relentless efforts by high quality companies to ensure the safety of their employees and local communities. Companies such as Infosys, Tata Consultancy Services (TCS), HDFC Bank and Hindustan Unilever are among the largest private employers in India. They have partnered with thousands of hospitals across the country to provide free vaccinations for their employees. The campuses of many IT services companies have been turned into vaccination centers. HDFC Bank has partnered with hotels across India to provide isolation facilities for affected staff, with online platforms to provide e-consultations with doctors. Bosch, a leading auto component company, has created Covid-care facilities for the broader community at its campus. In many other countries, such measures are the responsibility of governments. As usual, it has been the socially responsible private companies that are leading the efforts to battle Covid-19 in India.
The fund’s performance in May was strong. The key contributors to performance were Godrej Consumer Products, ICICI Bank and Colgate Palmolive India. Each of these is among the top five holdings of the fund.
Godrej Consumer Products announced the appointment of Mr Sudhir Sitapati as Group CEO. Mr. Sitapati has led several businesses at Unilever across India, Europe, South East Asia and Africa. His experience is likely to help Godrej Consumer Products accelerate the growth potential across its businesses.
ICICI Bank continues to benefit after its strong performance in the most recent quarter. Its competitive position is likely to continue strengthening as large state-owned banks and smaller non-bank finance companies struggle with weak balance sheets and poor asset quality.
Colgate Palmolive India reported strong quarterly performance. Its sales grew by 20% and profit after tax by 54% compared to the same period last year. Its management has increased the focus on the fast-growing modern trade and e-commerce distribution channels. Its strong pricing power and increasing share of premium products can also drive improvement its profitability over the medium term.
The key detractors were Blue Star Limited and Strides Pharma Science.
The decline in the share price of Blue Star was related to concerns about the impact of the second wave of the Covid-19 pandemic on customer demand. Our discussions with its management have strengthened our conviction in its medium-term prospects. They have launched a new range of more affordable air conditioners which should help the company continue gaining market share. Its management is also focused on driving cost efficiencies to improve its profitability.
Strides Pharma Science’s recent performance was affected by a weak flu season in its key US market. However, the company has a strong pipeline of new products which should help it gain further scale in its core markets. Its investments to build its product portfolio in emerging markets with low penetration should also help to strengthen its growth prospects over the coming periods. It is a toehold position in the portfolio.
*Source: Company data retrieved from company annual reports or other such investor reports. As at 31 May 2021 or otherwise noted.
The information contained within this document is generic in nature and does not contain or constitute investment or investment product advice. The information has been obtained from sources that First Sentier Investors (“FSI”) believes to be reliable and accurate at the time of issue but no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information. Neither FSI, nor any of its associates, nor any director, officer or employee accepts any liability whatsoever for any loss arising directly or indirectly from any use of this document.
This document has been prepared for general information purpose. It does not purport to be comprehensive or to render special advice. The views expressed herein are the views of the writer at the time of issue and may change over time. This is not an offer document, and does not constitute an investment recommendation. No person should rely on the content and/or act on the basis of any matter contained in this document without obtaining specific professional advice. The information in this document may not be reproduced in whole or in part or circulated without the prior consent of FSI. This document shall only be used and/or received in accordance with the applicable laws in the relevant jurisdiction.
Reference to specific securities (if any) is included for the purpose of illustration only and should not be construed as a recommendation to buy or sell the same. All securities mentioned herein may or may not form part of the holdings of First Sentier Investors’ portfolios at a certain point in time, and the holdings may change over time.
In Hong Kong, this document is issued by First Sentier Investors (Hong Kong) Limited and has not been reviewed by the Securities & Futures Commission in Hong Kong. In Singapore, this document is issued by First Sentier Investors (Singapore) whose company registration number is 196900420D. This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.
First Sentier Investors and FSSA Investment Managers are business names of First Sentier Investors (Hong Kong) Limited. First Sentier Investors (registration number 53236800B) and FSSA Investment Managers (registration number 53314080C) are business divisions of First Sentier Investors (Singapore). The FSSA Investment Managers logo is a trademark of the MUFG (as defined below) or an affiliate thereof.
First Sentier Investors (Hong Kong) Limited and First Sentier Investors (Singapore) are part of the investment management business of First Sentier Investors, which is ultimately owned by Mitsubishi UFJ Financial Group, Inc. (“MUFG”), a global financial group. First Sentier Investors includes a number of entities in different jurisdictions.
MUFG and its subsidiaries are not responsible for any statement or information contained in this document. Neither MUFG nor any of its subsidiaries guarantee the performance of any investment or entity referred to in this document or the repayment of capital. Any investments referred to are not deposits or other liabilities of MUFG or its subsidiaries, and are subject to investment risk, including loss of income and capital invested.